Senores Pharmaceuticals experienced a robust debut on the stock market, with its shares opening at ₹600 on the NSE—a 53.45% premium over the issue price of ₹391. On the BSE, it debuted at ₹593.70 per share, marking a 52% premium.
Senores Pharmaceuticals Limited IPO on Day 3 saw a total subscription of 93.69x, with Qualified Institutional Buyers (QIBs) at 94.66x, Non-Institutional Investors (NIIs) at 96.30x, Retail Institutional Investors (RIIs) at 90.46x, and Employees at 20.21x.
Also Read: Top Losers: Siemens and 9 other stocks that fell 15.81% this week
Senores Pharmaceuticals Limited founded in December 2017,develops and manufactures a diverse range of pharmaceutical products for regulated markets like the US, Canada, and the UK, and emerging markets. As of September 2024, the company offers 55 products in areas like antibiotics and anti-fungals, with extensive partnerships in India.
Senores Pharmaceuticals Ltd aims to enhance operational capacities and financial health by investing in subsidiaries, repaying debts, and boosting working capital to support growth and manufacturing expansions.
Disclaimer: The above article is written for educational purposes, and the companies’ data mentioned in the article may change with respect to time The securities quoted are exemplary and are not recommendatory.